|
|
BioSig Tech. (BSGM) & Electrophysiology Sector (related stock BSGM)
|
|
||
What We KnowWhat we know 1. BioSig has an FDA-approved device that is accepted by the key industry leaders in ablative procedures. The kind of guys you would want doing your own ablation should you need one. 2. BioSig has a very favorable agreement and almost unique 10-year agreement with the Mayo Clinic in 2017 (expanded in 2018/2019) to develop advanced clinical features and applications for its Pure EP system. In Nov. 2019 it was announced that three new patent and know-how licensing agreements were signed with the Mayo Clinic. (Link to licensing announcement) a. To establish and advance PureEP to develop solutions for treating autonomic nervous system disease. [The autonomic nervous system regulates the function of the body’s internal organs, such as heart rate, blood pressure, digestion, and body temperature. People with an autonomic disorder have trouble regulating one or more of these systems, which can result in fainting, lightheadedness, fluctuating blood pressure, and other symptoms.] b. “BioSig intends to take the licensed intellectual properties and products, which have been developed by Mayo Clinic over the last decade, through FDA approval, manufacturing, and commercialization. The development program will be run under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.” c. Check out Dr. Asirvatham’s profile here, along with his Focus Area section. (Link to Dr's profile) d. And I found this from August 2019 which listed Dr. Asirvatham in an AI-related study: (Link to Afib screening) e. And here are Patent indications for him. Note that two have publication dates from Jan. 2020 and list BioSig and Mayo as the applicants and Dr. Asirvatham as one of the Inventors. (Link to Dr's patents) f. Finally, check out this link to see the involvement by Paul Friedman, MD, Chair of Cardio Vascular Medicine at Mayo. (See Interests section.) (Link to Dr Friedman profile) g. So the merging of AI (Google) with Mayo and BioSig is opening new frontiers of potential treatments. 3. Because BioSig has a very accomplished Board of Directors a. O’Donnell – Multi positions as CEO, COB, PWC 2005 Life Sciences CEO of the Year, ran start-ups and solid medical device companies. b. Filler – General Counsel(GC) for Sherpa tech, was GC and VP of IP for Nanosys, chief IP counsel at Caliper Tech, and director of IP at Corvascular. c. Weild – former Vice Chairman of NASDAQ, former president of Prudential Financial, and has been invited to, and spoke at, the White House, Congress, SEC, OECD, and the G-20. d. Gallagher – 20 years Wall Street experience. Sr. Managing Dir./head of healthcare sales at Laidlaw, consultant for Athenex, BOD of Cingulate Therapeutics, etc. e. Foley – former COB of Wilmington Trust, former SVP ITT Corp, executive positions with International Paper, Mobil, and General Electric. Sits as a Trustee at many organizations. f. Navarro – Managing Partner at Gravitas Healthcare which is a strategic advisory firm specializing in emerging growth med device companies (in the past dozen years they have 30+ partnership transactions), also experience with investment banking, portfolio management, and research analysis. g. Pease – On air and online CNN commentator, spearheaded major equity initiatives for Neutrogena, Domino’s, Lifetime TV, L’Oreal Paris, Pizza Hut and Lane Bryant. h. Zeldis – i. Chief Medical Officer (CMO) and President of Clinical Research, Medical Affairs Drug Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc. ii. PhD in Molecular Biophysics and Biochemistry from Yale University iii. Was Assistant Professor of Medicine at the Harvard Medical School, iv. Was Associate Professor of Medicine at University of California, Davis v. Was Clinical Associate Professor of Medicine at Cornell Medical School vi. Named inventor on 43 US patents vii. Published 122 peer-reviewed articles viii. CEO of Celgene’s Global Health and Chief Medical Officer (CMO) of Celgene when it reached a $100 billion market cap. 4. BioSig announced a new subsidiary of its NeuroClear called ViralClear a. Nick Spring will be the CEO – at Merck ($181 billion company with one of its major focuses being vaccines) he led the live viral human vaccine area. Was CEO/Pres. of a medical device company, and Founder and CEO of Topaz Pharma taking it from a private company to FDA approval and then selling to Sanofi for $200 million+. b. ViralClear’s first focus will be developing Victromax to treat SARS-CO-2 coronavirus (COVID-19). This drug has already, for other indications i. Completed Phase I trial (Safety and dosing in humans) ii. Completed three Phase 2 trials (efficacy) c. The drug could be used in mono or combo therapies. 5. Tying it together a. Accomplished BioSig BOD with NASDAQ, Big Pharma, Biotech, Start-Up, and deals/merger experience. b. BioSig/NeuroClear is advancing with potentials outside cardiac ablation with top-tier Mayo personnel. c. New subsidiary ViralClear headed by a former Merck major player in live human vaccines experienced in all phases of corporate growth from Founder to FDA approval and acquisition. d. BioSig BOD member Zeldis, a biotech Hall of Famer, will be involved in some capacity with Victromax (via BOD oversight or something more?). I think we get more color in the coming weeks. |
return to message board, top of board |